UNICA IRIS Institutional Research Information System

MORELLI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 248.682
NA - Nord America 19.476
AS - Asia 7.684
SA - Sud America 1.289
AF - Africa 174
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 13
Totale 277.337
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 244.166
US - Stati Uniti d'America 19.252
SG - Singapore 2.995
CN - Cina 2.779
UA - Ucraina 1.489
BR - Brasile 1.012
SE - Svezia 834
VN - Vietnam 713
DE - Germania 526
FI - Finlandia 518
GB - Regno Unito 446
FR - Francia 382
HK - Hong Kong 306
IN - India 173
KR - Corea 172
CA - Canada 123
AR - Argentina 94
BD - Bangladesh 68
IQ - Iraq 66
RU - Federazione Russa 64
MX - Messico 63
JP - Giappone 58
ZA - Sudafrica 51
EC - Ecuador 46
ID - Indonesia 45
TR - Turchia 45
CO - Colombia 43
PK - Pakistan 41
NL - Olanda 35
PL - Polonia 34
BE - Belgio 27
ES - Italia 27
SA - Arabia Saudita 25
IL - Israele 23
MA - Marocco 23
VE - Venezuela 23
PH - Filippine 22
EG - Egitto 21
AT - Austria 20
CL - Cile 20
TN - Tunisia 19
IE - Irlanda 18
UZ - Uzbekistan 18
EU - Europa 17
KE - Kenya 16
MY - Malesia 16
PY - Paraguay 16
PE - Perù 14
CZ - Repubblica Ceca 13
ET - Etiopia 13
AE - Emirati Arabi Uniti 12
AZ - Azerbaigian 12
JM - Giamaica 12
NP - Nepal 11
TH - Thailandia 11
UY - Uruguay 11
AU - Australia 10
JO - Giordania 10
LT - Lituania 10
RO - Romania 10
AL - Albania 9
BO - Bolivia 9
DZ - Algeria 8
KZ - Kazakistan 8
OM - Oman 8
TW - Taiwan 8
PT - Portogallo 7
BY - Bielorussia 6
CH - Svizzera 6
GE - Georgia 6
IR - Iran 6
CR - Costa Rica 5
MN - Mongolia 5
MU - Mauritius 5
NO - Norvegia 5
AO - Angola 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
NG - Nigeria 4
PS - Palestinian Territory 4
SV - El Salvador 4
BG - Bulgaria 3
BH - Bahrain 3
CI - Costa d'Avorio 3
DK - Danimarca 3
HR - Croazia 3
KG - Kirghizistan 3
LB - Libano 3
NI - Nicaragua 3
QA - Qatar 3
RS - Serbia 3
BA - Bosnia-Erzegovina 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
KH - Cambogia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PA - Panama 2
SI - Slovenia 2
Totale 277.312
Salva come PNG Salva come JPEG
Città #
Cagliari 237.441
Uta 5.888
Fairfield 2.329
Woodbridge 1.633
Ashburn 1.609
Singapore 1.498
Chandler 1.273
Houston 1.103
Seattle 945
Wilmington 918
San Jose 888
Ann Arbor 849
Boardman 814
Jacksonville 798
Dallas 790
Cambridge 757
Nyköping 508
Beijing 476
Dearborn 316
Los Angeles 316
Helsinki 273
Nanjing 272
Hong Kong 271
Lauterbourg 227
Hefei 223
New York 222
Ho Chi Minh City 211
Boston 202
Santa Clara 186
Seoul 162
The Dalles 161
Shanghai 156
Hanoi 141
San Diego 132
Buffalo 128
Hangzhou 113
Council Bluffs 111
Milan 95
Shenyang 89
São Paulo 83
Redwood City 78
Hebei 73
Dong Ket 70
Toronto 70
Guangzhou 67
Nanchang 63
London 62
Changsha 58
Mountain View 58
Munich 58
Redondo Beach 57
Verona 50
Chicago 49
Jiaxing 49
Tianjin 48
Norwalk 43
Rome 41
Tokyo 41
Frankfurt am Main 40
Jinan 40
Da Nang 39
Brooklyn 35
Zhengzhou 35
Washington 33
Haiphong 31
Rio de Janeiro 31
Sassari 30
Auburn Hills 29
Orem 29
Chennai 26
Baghdad 25
Orange 25
Brussels 23
Ningbo 23
Atlanta 20
Montreal 20
Phoenix 20
Warsaw 20
Belo Horizonte 19
Brasília 19
Curitiba 19
Falls Church 19
Nuremberg 19
Johannesburg 18
Pune 18
Paris 17
Porto Alegre 17
Dhaka 16
Mexico City 16
Tashkent 16
Dublin 15
Indiana 15
Kunming 15
Manchester 15
New Delhi 15
Oristano 15
Stockholm 15
Columbus 14
Wuhan 14
Amsterdam 13
Totale 266.575
Salva come PNG Salva come JPEG
Nome #
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.329
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.290
Odor identification performance in idiopathic Parkinson’s disease is associated with gender and the genetic variability of the olfactory binding protein 3.688
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3.642
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.544
Role of Adenosine in the basal Ganglia 3.357
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.118
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? 3.013
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms 2.960
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.937
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.867
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.849
Modulation of rat 50-kHz ultrasonic vocalizations by glucocorticoid signaling: possible relevance to reward and motivation 2.826
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2.778
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.762
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.722
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.700
Methylxanthines and drug dependence: interactions and toxicity 2.699
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.685
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.662
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.627
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.538
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage 2.520
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity 2.519
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2.512
Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls 2.506
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 2.464
Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50kHz Ultrasonic Vocalizations 2.427
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 2.406
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation 2.399
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 2.385
Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study 2.374
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease 2.334
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 2.318
null 2.277
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex 2.273
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.204
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.168
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.120
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2.106
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.096
NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease 2.009
Preface [ to The Adenosinergic System. A Non-Dopaminergic Target in Parkinson’s Disease] 1.987
Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug 1.984
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.966
Neurochemical and neurotoxic effects of MDMA (Ecstasy) and caffeine after chronic combined administration in mice 1.959
Metformin prevented dopaminergic neurotoxicity induced by 3,4-Methylenedioxymethamphetamine administration 1.918
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.884
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease 1.834
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.828
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease 1.825
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist 1.824
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions 1.806
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 1.804
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of Parkinson’s disease 1.800
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1.791
Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques 1.724
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.703
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.649
Antiparkinsonian actions and interactions of adenosine antagonists 1.641
The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies 1.589
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.555
Gender-dependent behavioral and biochemical differences in the A53T genetic mouse model of Parkinson’s disease 1.456
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.416
Adenosine signaling in the basal ganglia 1.301
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists 1.292
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.285
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.282
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 1.208
null 1.194
The 6-hydroxydopamine model of Parkinson's disease 1.186
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.176
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.176
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.168
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 1.141
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 1.134
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice 1.129
Function of dopamine in the extrapyramidal and limbic systems 1.121
null 1.108
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.106
A2A receptor antagonism and dyskinesia in Parkinson’s Disease 1.105
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties 1.094
6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease 1.089
Caffeine Consumption and Changes in the Function of Dopaminergic Transmission: Evidence of a Hyperdopaminergic State in Rats Subchronically Treated with Caffeine 1.086
Adenosine A2A receptors and Parkinson's disease 1.071
Anxyiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity 1.027
Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse 1.024
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease 1.024
null 1.012
Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice 990
Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences 990
null 981
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 977
null 967
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 967
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 955
Effects of docosanyl ferulate, a constituent of Withania somnifera, on ethanol- and morphine-elicited conditioned place preference and ERK phosphorylation in the accumbens shell of CD1 mice 955
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 951
Birth asphyxia as the major complication in newborns: Moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care 946
Totale 192.822
Salva come PNG Salva come JPEG
Categoria #
all - tutte 381.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 381.345
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218.411 0 0 0 0 0 0 0 0 0 3.401 2.864 2.146
2021/202213.605 1.299 1.202 874 806 878 1.004 1.109 716 832 1.321 1.539 2.025
2022/202321.093 1.985 2.506 1.915 1.779 1.902 2.223 1.052 1.816 1.484 1.548 1.991 892
2023/202424.574 1.019 971 1.077 1.426 2.404 4.033 3.710 1.751 1.002 2.055 2.489 2.637
2024/202537.231 5.784 7.130 6.779 5.143 2.705 3.688 3.579 324 599 466 468 566
2025/202615.390 955 742 1.753 1.447 1.083 977 4.995 1.016 1.044 1.378 0 0
Totale 278.129